Cannabiz informs, educates and connects cannabis industry professionals through our website, weekly industry newsletter, market intelligence, industry reports, webinars and business consulting services.
We operate within the Therapeutic Goods Administration’s advertising guidance.
As such, we do not allow the advertising of medicinal cannabis products on any of our channels.
We do report company news and product launches in order to educate and inform our B2B audience.
We are editorially independent and do not endorse any company or product. The fact that we write about a company or product is not — and should not be read as — an endorsement of any kind.
Our premium membership offering is a paid service which gives members full access to Cannabiz content.
While we do have some non-industry readers among our free audience, they are never exposed to product advertising and we do not share product stories on our social media channels.
Although acceptable under fair dealing exceptions, we have taken a strategic decision to avoid publishing images of products sold in Australia or New Zealand where possible. If you spot one on the site, please let us know.
We do accept sponsored content from industry partners wanting to reach our audience of cannabis industry professionals. Such contributions are edited by a member of the Cannabiz editorial team, must comply with this policy and contribute positively to the Cannabiz conversation. All sponsored content is labelled as such.
We also accept guest contributions from industry leaders under the terms of this policy. Our guide to submitting a guest post can be found here.
Should you have any complaints about our content, or comments on this policy, please email firstname.lastname@example.org.